Summit Wireless to host special shareholder meeting » 17:3803/2903/29/20
Special Shareholder Meeting to approve an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of all of the outstanding shares of common stock will be held in Hillsboro, Oregon on March 31 at 5 pm.
Ocugen files $75M mixed securities shelf 17:4103/2703/27/20
Can-Fite BioPharma files to sell 74.89M ordinary shares for holders » 16:4603/2703/27/20
Represented by 2,496,249…
Represented by 2,496,249 American Depositary Shares.
electroCore enters into $25M common stock purchase agreement with Lincoln Park » 16:0603/2703/27/20
electroCore announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund. Under the terms of the purchase agreement, electroCore will, at its sole option and discretion, have the right, but not the obligation to sell up to $25M of its common stock to Lincoln Park over a 36-month period.
Fly Intel: Pre-market Movers » 09:1403/2703/27/20
WW, SCWX, GME, KBH, ALT, OCGN, QFIN, LULU, TXMD, HTZ, GPS
Check out this morning's…
Morgan Stanley cuts Quest, upgrades Charles River in Healthcare Service shake-up » 08:5003/2703/27/20
As previously reported,…
As previously reported, Morgan Stanley analyst Ricky Goldwasser downgraded Quest Diagnostics (DGX) to Equal Weight from Overweight with a $95 price target, down from $117. Labs "are front and center in COVID screening," but volume headwinds from reduced physician office visits will likely counterbalance any COVID benefits, Goldwasser said. Meanwhile, she also upgraded Charles River Labs (CRL) to Overweight from Equal Weight with a $152 price target, down from $176, noting that CROs have been the laggards in our healthcare services due to a combination of an expected slowdown in near-term trial activity, concerns around leverage and worries about weak biotech funding.
Capstone Turbine partners with NYPA, Brenmiller Energy for SUNY Purchase project » 08:1403/2703/27/20
Capstone Turbine announced that it has partnered with the New York Power Authority, or NYPA, and Brenmiller Energy on a groundbreaking thermal energy storage project for Purchase College, State University of New York, or SUNY. The project received a one million dollar grant from the Israel-United States Binational Industrial Research and Development, or BIRD, Foundation to investigate low emission thermal energy storage as a means to increase the efficiency of standard combined heat and power, or CHP, systems. The installation will serve as a demonstration project for innovative thermal energy storage technology in New York. The collaboration is one of many projects deployed as part of New York State's Energy Storage Roadmap that includes energy storage targets of 1,500 megawatts by 2025-the equivalent electricity demand of one-fifth of all New York homes.
Hoth Therapeutics, HaloVax to advance application of VaxCelerate » 08:0603/2703/27/20
HaloVax, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, announced they have reached an agreement with Hoth Therapeutics to advance an application of VaxCelerate, a self-assembling vaccine platform licensed from the Vaccine and Immunotherapy Center at Massachusetts General Hospital, to develop a vaccine designed to protect patients at risk of COVID-19 infection. Voltron Therapeutics has acquired an exclusive license to this technology. HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19. The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents. The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense. These same principles are being applied to developing a vaccine against the COVID-19 pandemic.
Ocugen expects topline results for Phase 3 study of OCU300 by year-end » 07:3503/2703/27/20
In December 2019, Ocugen…
In December 2019, Ocugen announced 50% enrollment in its Phase 3 trial, and as of March 20, 2020, Ocugen has completed over 95% of the planned enrollment. Ocugen is anticipating topline results by the end of the year.
Ocugen reports FY19 EPS ($1.26) vs. ($3.67) last year » 07:3403/2703/27/20
"We are extremely…
"We are extremely pleased with the progress we have made in enrolling patients in our Phase 3 clinical trial for OCU300, an orphan drug candidate for ocular graft versus host disease. Based on current enrollment, we anticipate topline results by the end of the year," commented Shankar Musunuri, PhD, MBA, Chairman, CEO and Co-Founder of Ocugen. "The publication of preclinical data on OCU400 in Nature Gene Therapy earlier this month is a key achievement for this program. We continue to advance IND-enabling studies toward bringing this potential breakthrough modifier gene therapy platform to patients in a Phase 1/2a clinical trial for OCU400 in 2021. Similar to the situation with virtually all other biopharmaceutical companies, we are also assessing the potential impact of ongoing COVID-19 pandemic-related events on our programs and plans. We are grateful to healthcare professionals and others who are working hard to address and mitigate the challenges presented by the virus."